JPT Peptide Technologies GmbH Announces Cooperation On Systematic Identification Of Tuberculosis T-Cell Epitopes With Oregon Health & Science University (OHSU) 
10/19/2005 5:09:25 PM

BERLIN--(BUSINESS WIRE)--July 6, 2005--JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of Jerini AG, today announced a collaboration with Oregon Health & Science University (OHSU) for the systematic and rapid discovery of T-cell epitopes to accelerate the development of vaccines against tuberculosis (TB). The collaboration combines OHSU's outstanding research and expertise to isolate and clone CD8+ cells from latent TB patients with JPT's proprietary SPOT(TM) technology to produce very large numbers of peptides. David and Deborah Lewinsohn at OHSU are principal investigators of an NIH/ NIAID biodefense contract to study tuberculosis. Their teams determine relevant antigens within infected cells, which subsequently will be used to identify characteristic parts of these proteins (epitopes) that are required by the CD8+ cells to activate the immune response against these bacteria.